Friday, 15 Dec 2017

You are here

CDC Lyme Disease Surveillance Report

Lyme disease, caused by the spirochete Borrelia burdofgeri, is the most common vector-borne illness reported in the U.S. Cases occur mainly in the Northeast, Mid-Atlantic and upper Midwest as well as certain areas of the Pacific coast, with a geographic distribution based on residence of Ixodes scapularis (Ixodes pacificus on the West Coast), the vectors that transmits Lyme disease.

Lyme disease has been a reportable disease since 1991, with cases reported to the Health Department by both physicians and laboratories. Confirmed or probable cases are then reported to the CDC through the National Notifiable Diseases Surveillance System.

MMWR recently published surveillance data for Lyme Disease in the U.S. from 2008-2015. States with an average annual incidence ≥ 10 confirmed cases per 100,000 population were considered high incidence. During this time period 275,589 cases of Lyme were reported to the CDC and most cases were from regions previously considered to be high incidence.

According to the CDC surveillance report, the top 7 states for Lyme disease in 2015 include

  1. Vermont (78.4 per 100000/yr)
  2. Maine (74.7 per 100000/yr)
  3. Pennsylvania (57.5 per 100000/yr)
  4. Rhode Island (53.4 per 100000/yr)
  5. Connecticut (52.2 per 100000/yr)
  6. New Jersey (43.9 per 100000/yr)
  7. Massachussetts (43 per 100000/yr).

For the most part these counts have remained stable over the years; however, incidence is rising in states that neighbor these regions. Demographics of reported cases are similar to in the past, but in lower incidence areas there were more cases in younger females compared to the past.

We can take away from this that Lyme disease continues to concentrate in known high-incidence areas although the geographic distribution seems to be spreading. This will add to the continuing public health challenge that is Lyme disease, and Lyme should be considered in a patient with a  suggestive clinical presentation even if they are not from a high risk area.  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Kidney Dysfunction Frequent in RA

Renal dysfunction is common among patients with rheumatoid arthritis (RA), particularly among older patients, women, and those with hypertension, Japanese researchers reported.

Using absolute estimated glomerular filtration rates (eGFR), 33.8% of patients had renal dysfunction, according to Shunsuke Mori, MD, of Kumamoto Saishunsou National Hospital in Kohshi, and colleagues. 

Offspring of RA Women Have Higher Risk of RA and Other Diseases

Despite a growing body of evidence suggesting that maternal health is more important than maternal medications to fetal and infant outcomes, little is known about the long term oucomes of infants born to mothers with rheumatoid arthritis (RA). Using Danish population data, researchers have shown in utero exposure to maternal RA is associated with an increased risk of thyroid disease, and an increased risk of future RA.

Vitamin D Insensitivity in the Rheumatoid Joint

Researchers from the University of Birmingham have shown that while Vitamin D may be effective at preventing the onset of inflammation, it is less effective once inflammatory disease is established - largely because, once established, rheumatoid arthritis leads to vitamin D insensitivity. (Citation source https://buff.ly/2iGHYmI)

Stroke Increased in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, inflammatory disease with systemic effects beyond the joints. While RA patients are known to have signficantly higher risks for cardiovascular disease and venous thromboembolic events, an association with stroke (CVA) is unclear.

A study claims data from Israel analyzed 11,782 RA patients and 57,973 age- and gender-matched controls.

Comparative Risk of Biologic Therapies in RA Patients Undergoing Elective Arthroplasty

During today’s plenary session Micheal D. George, et al. presented results of a study that sought to compare risk of post-op infections in RA patients undergoing arthroplasty exposed to biologic DMARDs versus methotrexate.